Browse our 650+ Publications​

Latest Publications

Venetoclax-Dexamethasone VersusPomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study

Popat R, et al.
Journal of Clinical Oncology
December 2025
Authors and Affiliates
Rakesh Popat, MD, PhD1 ; Meral Beksac, MD2 ; Meletios A. Dimopoulos, MD3,4 ; Moshe E. Gatt, MD5 ; Francesca Gay, MD6 ;Jae-Cheol Jo, MD, PhD7 ; Prashant Kapoor, MD8 ; Eirini Katodritou, MD, PhD9 ; K. Martin Kort¨um, MD10 ; Silvia Ling, PhD, MBBS11 ;Chandramouli Nagarajan, MD12 ; Kenshi Suzuki, MD, PhD13; Lugui Qiu, MD14; Maika Onishi, MD15; Grace Ku, MD15 ; Monique Dail, PhD15 ;Nabanita Mukherjee, PhD16; Jeremy A. Ross, PhD16; Mohamed Ali Badawi, PhD16; Mary Jean Fusco, MD16; Edyta Dobkowska, MD17;Emma Arriola, PhD18; Orlando F. Bueno, MD, PhD16; Nizar J. Bahlis, MD19 ; Shinsuke Iida, MD20 ; Philippe Moreau, MD21; Jason Valent, MD22; andMar´ıa-Victoria Mateos, MD, PhD231Haematology Department, University College London Hospitals NHSFoundation Trust, London, United Kingdom2Department of Hematology, Ankara University, Ankara, Turkey3Department of Clinical Therapeutics, School of Medicine, National andKapodistrian University of Athens, Athens, Greece4Department of Medicine, Korea University, Seoul, South Korea5Department of Hematology, Hadassah Hebrew University MedicalCenter, Jerusalem, Israel6Division of Hematology 1, Department of Biotechnology and HealthScience, Azienda Ospedaliero-Universitaria Citt `a della Salute e dellaScienza, University of Torino, Torino, Italy7Department of Hematology and Oncology, Ulsan University Hospital,University of Ulsan College of Medicine, Ulsan, Korea8Division of Hematology, Mayo Clinic, Rochester, MN9Department of Hematology, Theagenion Cancer Hospital, Thessaloniki,Greece 10Department of Internal Medicine II, W¨urzburg University Hospital,University of W¨urzburg, W¨urzburg, Germany11Department of Haematology, Liverpool Hospital, Sydney, NSW,Australia12Department of Haematology, Singapore General Hospital, Singapore,Singapore13Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center,Tokyo, Japan14National Clinical Research Center for Hematological Disorders & StateKey Laboratory of Experimental Hematology, Institute of Hematologyand Blood Diseases Hospital, Chinese Academy of Medical Sciencesand Peking Union Medical College, Tianjin, China15Genentech Inc, South San Francisco, CA16AbbVie Inc, North Chicago, IL17Pharmacyclics Switzerland GmbH, An AbbVie Company,Schaffhausen, Switzerland18AbbVie, Maidenhead, United Kingdom19Arnie Charbonneau Cancer Institute, University of Calgary, Calgary,AB, Canada20Department of Hematology and Oncology, Nagoya City UniversityGraduate School of Medical Sciences, Nagoya, Japan21Department of Hematology, University Hospital Hˆotel-Dieu, Nantes,France22Department of Hematology and Medical Oncology, Cleveland ClinicFoundation, Taussig Cancer Institute, Cleveland, OH23Haematology Department, University Hospital of Salamanca, Institutode Investigaci ´on Biom´edica de Salamanca and Institute of CancerMolecular and Cellular Biology and CIBERONC, Salamanca, Spain

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in theLINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses

Lee H, et al.
Clinical Lymphoma Myeloma & Leukemia
November 2025
Authors and Affiliates
Hans C. Lee,1 Jeffrey A. Zonder,2 Madhav V. Dhodapkar,3 Sundar Jagannath,4 James E. Hoffman,5 Attaya Suvannasankha,6 Mansi R. Shah,7 Suzanne Lentzsch,8 Rachid Baz,9 Joseph J. Maly,10 Swathi Namburi,11 Matthew J. Pianko,12 Jing Christine Ye,1 Ka Lung Wu,13 Rebecca Silbermann,14 Chang-Ki Min,15 Marie-Christiane Vekemans,16 Markus Munder,17 Ja Min Byun,18 Joaquín Martínez-Lopez,19 Michelle DeVeaux,20 Tito Roccia,20 Dhruti Chokshi,20 Megan Seraphin,20 Kate Knorr,20 Anita Boyapati,20 Anasuya Hazra,20 Karen Rodriguez Lorenc,20 Glenn S. Kroog,20 Naresh Bumma,21 Joshua Richter4 1The University of Texas MD Anderson Cancer Center, Houston, TX 2Karmanos Cancer Institute, Detroit, MI 3Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 4Icahn School of Medicine at Mount Sinai, New York, NY 5Department of Medicine, University of Miami Health System, Miami, FL 6Department of Medicine, Indiana University Simon Cancer Center and Richard L. Roudebush VAMC, Indianapolis, IN 7Department of Medicine, Rutgers Cancer Institute, New Brunswick, NJ 8Columbia University Irving Medical Center, New York, NY 9Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL 10Norton Cancer Institute, Louisville, KY 11Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Seattle, WA 12Department of Internal Medicine, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 13Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium 14Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 15Department of Hematology, College of Medicine, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea 16Hematology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium 17Department of Internal Medicine III, Universitätsmedizin Mainz, Mainz, Germany 18Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea 19Hospital Universitario 12 de Octubre, i+12, School of Medicine Universidad Complutense, CNIO, Madrid, Spain 20Regeneron Pharmaceuticals, Inc., Tarrytown, NY 21Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant

Derman BA, et al.
Hemasphere
August 2025
Authors and Affiliates
Benjamin A. Derman1 | Jennifer Cooperrider1 | Anna Pula1,2 | Heidi Simmons3 | Tadeusz Kubicki1,4 | Jeffrey Zonder5 | Aimaz Afrough6 | David Grinblatt7 | Jacalyn Rosenblatt8 | Larry D. Anderson Jr.6 | Andrew Kin5 | David Avigan6 | Sunil Narula1 | Shayan Rayani1 | Ken Jiang1 | Ajay Major9 | Theodore Karrison1 | Allison Jacob3 | Andrzej J. Jakubowiak1 1University of Chicago, Chicago, Illinois, USA 2Department of Hematology, Medical University of Lodz, Łódź, Poland 3Adaptive Biotechnologies, Seattle, Washington, USA 4Poznan University of Medical Sciences, Poznan, Poland 5Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA 6Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA 7Endeavor Health, Evanston, Illinois, USA 8Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA 9University of Colorado, Denver, Colorado, USA

Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis

Vianna P, et al.
Blood
July 2025
Authors and Affiliates
Pedro Vianna1,2,3, Rajshekar Chakraborty4, Shahrier Hossain2, Divaya Bhutani4, Shannon Miller2, Annemarie Rossi2, Sarah A. M. Cuddy3,5, Rodney H. Falk3,5, Suzanne Lentzsch4, Jacob Laubach2,3, Giada Bianchi1,2,3* 1Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 3Harvard Medical School, Boston, MA; 4Division of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY, 5Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial

Hungria V, et al.
Lancet Oncology
July 2025
Authors and Affiliates
Vania Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P Joy Ho, Roman Hájek, Kihyun Kim, Sebastian Grosicki, Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Gracia Aparecida Martinez, Anna Sureda Balarí, Irwindeep Sandhu, Claudio Cerchione, Peter Ganly, Meletios A Dimopoulos, Chengcheng Fu, Mamta Garg, Al-Ola Abdallah, Moshe E Gatt, Albert Oriol Rocafiguera, Michele Cavo, Robert Rifkin, Tomoaki Fujisaki, Michał Mielnik, Joseph Ficek, Alejandro Mantero, Nick Pirooz, Sybil Varghese, Joe Lee, Astrid McKeown, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy-Ghanta, Pralay Mukhopadhyay, Jacqueline Nielsen, Joanna Opalinska, María-Victoria Mateos, on behalf of the DREAMM-7 study investigators Clinica São Germano, São Paulo, Brazil (V Hungria MD); Medical University of Łódź, Łódź, Poland (Prof P Robak MD); Samodzielny Publiczny Szpital Kliniczny, Lublin, Poland (Prof M Hus MD, M Mielnik MD); Gorodskaya Klinicheskaya Bol’nitsa Im Sp Botkina, Moscow, Russia (V Zherebtsova MD); Royal North Shore Hospital, Sydney, NSW, Australia (Prof C Ward MD); Royal Prince Alfred Hospital, Camperdown, NSW, Australia (Prof P J Ho MBBS); University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic (Prof R Hájek MD); Sungkyunkwan University, Samsung Medical Center, Seoul, South Korea (Prof K Kim MD); Medical University of Silesia, Katowice, Poland (Prof S Grosicki MD); Pindara Private Hospital, Gold Coast, QLD, Australia (H Sia MBBS); Liverpool Hospital, Sydney, NSW, Australia (A Bryant PhD); Universidade da Região de Joinville and Centro de Hematologia e Oncologia, Joinville, Santa Catarina, Brazil (Prof M Pitombeira de Lacerda MD); Hospital das Clínicas and Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil (G A Martinez MD); Institut Català d’Oncologia- L’Hospitalet L.-Barcelona, Barcelona, Spain (A Sureda Balarí MD); Cross Cancer Institute, Edmonton, AB, Canada (I Sandhu MD); Hematology Unit, Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST IRCCS, Meldola, Forlì-Cesena, Italy (C Cerchione MD); Christchurch Hospital, Christchurch, New Zealand (P Ganly PhD); School of Medicine, National and Kapodistrian University of Athens, Athens, Greece (Prof M A Dimopoulos MD); Korea University, Seoul, South Korea (Prof M A Dimopoulos); The First Affiliated Hospital of Soochow University, Jiangsu, China (Prof C Fu MD); University Hospitals of Leicester NHS Trust, Leicester, UK (M Garg MD); University of Kansas Cancer Center, Fairway, KS, USA (A-O Abdallah MD); Department of Haematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel (M E Gatt MD); Institut Català d’Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona, Spain (A Oriol Rocafiguera MD); Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy (Prof M Cavo MD); Rocky Mountain Cancer Centers— Denver—Midtown, Denver, CO, USA (R Rifkin MD); Matsuyama Red Cross Hospital, Matsuyama, Japan (T Fujisaki MD); GSK, Collegeville, PA, USA (J Ficek PhD, A Mantero PhD, N Pirooz MHA, S Varghese MBBS, R Rogers MS, S Roy-Ghanta MD, P Mukhopadhyay PhD, J Opalinska MD); GSK, London, UK (J Lee PhD, L Eccersley PhD); GSK, Stevenage, UK (A McKeown PhD); GSK, Mississauga, ON, Canada (H Baig BS); GSK, Chicago, IL, USA (J Nielsen PhD); Instituto de Investigación Biomédica de Salamanca, Hospital Universitario de Salamanca– IBSAL–CIC–Ciberonc, Salamanca, Spain (M-V Mateos MD)

Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial

Izutsu K, et al.
Leukemia Lymphoma
July 2025
Authors and Affiliates
Koji Izutsua, Daigo Akahaneb, Tomomi Toubaic, Toko Saitod, Yuko Mishimae, Tomoaki Fujisakif, Momoko Nishikorig, Takahiro Kumodeh, Youko Suehiroi, Kenji Ishitsukaj, Rebekah Conlonk, Ami Takahashil, Barbara D’Angelo Månssonm, Elena Favarom and Noriko Fukuharan aDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan; bDepartment of Hematology, Tokyo Medical University, Tokyo, Japan; cDepartment of Internal Medicine III, Division of Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, Japan; dDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan; eDepartment of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; fDepartment of Hematology, Japan Red Cross Society, Matsuyama Red Cross Hospital, Matsuyama, Japan; gDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; hDepartment of Hematology and Rheumatology, Kindai University, Osaka, Japan; iDepartment of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; jDepartment of Hematology and Rheumatology, Kagoshima University, Kagoshima, Japan; kAbbVie, North Chicago, IL, USA; lGenmab, Tokyo, Japan; mGenmab, Copenhagen, Denmark; nDepartment of Hematology, Tohoku University, Sendai, Japan

Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study

Kumar S, et al.
Lancet Haematology
June 2025
Authors and Affiliates
Shaji K Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto, Vania Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Maika Onishi, Grace Ku, Rajvineeth Pothacamury, Muhammad Jalaluddin, Jiewei Zeng, Jeremy A Ross, Edyta Dobkowska, Philippe Moreau Mayo Clinic, Rochester, MN, USA (Prof S K Kumar MD); Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia (Prof S J Harrison PhD); Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia (Prof S J Harrison); IRCCS Azienda Ospedaliero- Universitaria di Bologna, Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy (Prof M Cavo MD); Hematology Service Hospital La Fe, IIS La Fe, and School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain (Prof J de la Rubia MD); University College London Hospitals NHS Foundation Trust, London, UK (R Popat FRCPath); Duke University Medical Center, Durham, NC, USA (Prof C Gasparetto MD); Clinica São Germano, São Paulo, Brazil (Prof V Hungria MD); Asklepios Tumorzentrum Hamburg, AK Altona and AK St Georg, Hamburg, Germany (H Salwender MD); Japanese Red Cross Medical Center, Tokyo, Japan (Prof K Suzuki MD); Seoul National University, Seoul, South Korea (Prof I Kim MD); Genentech, Inc, South San Francisco, CA, USA (M Onishi MD, G Ku MD); AbbVie, North Chicago, IL, USA (R Pothacamury MD, M Jalaluddin PhD, J Zeng PhD, J A Ross PhD); AbbVie, Schaffhausen, Switzerland (E Dobkowska MD); University Hospital Hôtel-Dieu, Nantes, France (Prof P Moreau MD)

Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Lee H, et al.
Clin Lymphoma Myeloma Leuk
June 2025
Authors and Affiliates
Hans C. Lee,1 Naresh Bumma,2 Joshua Richter,3 Jeffrey A. Zonder,4James E. Hoffman,5 Zheng-Yi Zhou,6 Viviana García-Horton,6 Mirko Fillbrunn,6Hongjue Wang,6 Matthew Mattera,6 Wenxin Ma,6 Timothy J. Inocencio,7Yingxin Xu,7 Evelien Bergrath,7 James Harnett,7 Tito Roccia,7 Kate Knorr,7Glenn S. Kroog,7 Karen Rodriguez Lorenc,7 Qiufei Ma,7 Sundar Jagannath3 1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX2 Division of Hematology/Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH3 Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY4 Department of Hematology and Oncology, Karmanos Cancer Institute, Detroit, MI5 Department of Medicine, Division of Hematology/Oncology, University of Miami Health System, Miami, FL6 Analysis Group, Inc., Boston, MA7 Department of Oncology, Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma

Perrot A, et al.
June 2025
Authors and Affiliates
Aurore Perrot, M.D.,1 Jérôme Lambert, Ph.D.,2 Cyrille Hulin, M.D.,3 Andrea Pieragostini, M.D.,4 Lionel Karlin, M.D.,5 Bertrand Arnulf, M.D.,6 Philippe Rey, M.D.,7 Laurent Garderet, M.D.,8 Margaret Macro, M.D.,9 Martine Escoffre‑Barbe, M.D.,10 Julie Gay, M.D.,11 Thomas Chalopin, M.D.,12 Romain Gounot, M.D.,13 Jean‑Marc Schiano, M.D.,14 Mohamad Mohty, M.D.,15 Xavier Leleu, M.D.,16 Salomon Manier, M.D.,17 Clara Mariette, M.D.,18 Carine Chaleteix, M.D.,19 Thorsten Braun, M.D.,20 Bernard De Prijck, M.D.,21 Hervé Avet‑Loiseau, M.D.,22 Jean‑Yves Mary, Ph.D.,2 Jill Corre, Pharm.D.,22 Philippe Moreau, M.D.,23 and Cyrille Touzeau, M.D.23 1 Service Hématologie, Hôpital Universitaire de Toulouse Oncopole, Université de Toulouse, Toulouse, France; 2 Biostatistics and Medical Information Department, Hôpital St. Louis, Paris; 3 Service d’Hématologie, Hôpital Haut Lévêque, Centre Hospitalier Universitaire (CHU) de Bordeaux, Pessac, France; 4 Service Hématologie, Hôpital Universitaire de Dijon, Dijon, France; 5 Service Hématologie, Hôpital Universitaire Lyon Sud, Pierre-Bénite, France; 6 Hôpital Universitaire St. Louis, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris; 7 Centre Léon Bérard, Lyon, France; 8 Service Hématologie, Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Paris; 9 Service Hématologie, Institut Hématologie de Basse Normandie, Hôpital Universitaire de Caen, Caen, France; 10 Service Hématologie, Hôpital Universitaire de Rennes, Rennes, France; 11 Hôpital de Bayonne, Bayonne, France; 12 Service Hématologie, Hôpital Universitaire de Tours, Tours, France; 13 Service Hématologie, Hôpital Henri Mondor, Créteil, France; 14 Service Hématologie, Institut Paoli- Calmettes, Marseille, France; 15 Service Hématologie, Hôpital Universitaire St. Antoine, AP-HP, Université Sorbonne, Paris; 16 Service Hématologie, Hôpital Universitaire de Poitiers, Poitiers, France; 17 Service Hématologie, Hôpital Universitaire de Lille, Lille, France; 18 Service Hématologie, Hôpital CHU de Grenoble, Grenoble, France; 19 Service Hématologie, Hôpital Universitaire de Clermont-Ferrand, Clermont-Ferrand, France; 20 Service Hématologie, Hôpital Avicenne, AP-HP, Paris; 21 Service Hématologie, Hôpital Universitaire de Liège, Liège, Belgium; 22 Unité Génomique du Myélome, Hôpital Universitaire de Toulouse Oncopole, Université de Toulouse, Toulouse, France; 23 Service Hématologie, Hôpital Universitaire